odronextamab
regeneron
['fil,veral,12', 'odronextamab', ' apa ', 'elm-2', 'lymsm', 'nct03888105', 'dlbcl']
congress | #ash22
won-seog kim presented results from the elm-2 study, of heavily pre-treated pts with dlbcl treated with odronextamab. orr was 49.2, with 66.4% 12 month duration of cr. crs was the most common ae, with no grade 4 or 5 crs.
#lymsm #medicalcongress #hematology 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm